Interstitial lung disease after re-administration of gefitinib in a responder with no adverse effects during the first administration: a case report
Gefitinib-related interstitial lung disease (ILD) has been reported as a serious adverse effect, associated with a high mortality. Recently, it was reported that gefitinib may be effective again following re-administration in cases with a previous history of response to gefitinib. However, there have been no reports on the safety of re-administration of gefitinib. We report the case of a patient who developed ILD after being restarted on gefitinib, having shown complete response, with no serious adverse effects, during/after the first administration. Readministration of gefitinib should be considered cautiously, even if the previous administration was associated with no side effects. (Accepted on June 23, 2011)
